A Productive Quarter for Cancer Treatment
The second quarter of 2026 delivered six FDA oncology approvals covering some of the most common and most difficult-to-treat cancer types in the United States. From a precision therapy targeting a specific genetic alteration in prostate cancer to an antibody-drug conjugate now cleared for first-line use in triple-negative breast cancer, the approvals reflect a pipeline that has been steadily maturing across immunotherapy, targeted inhibitors, and antibody-based delivery systems.
